This is particularly relevant given the recent reports of clinical activity using the ADCs in HER2-low metastatic breast cancers, and the possibility that some strategies of targeting HER2 might be effective in early-stage HER2-low disease as well [19, 20]. The gene discussed is ERBB2; the disease is breast carcinoma.